Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

One key takeaway was that women faced a higher MI risk than men, but only for the first 30 days. 

Also, researchers noted, cryoballoon ablation was linked to a lower risk of cardiac tamponade than radiofrequency ablation. The study included data from nearly 60,000 hospitalizations.

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said. 

The recommendations were developed by a writing group comprised of experts from different specialties, offering an array of perspectives and approaches.

The device, which gained FDA approval in 2021, was part of a voluntary recall in 2022 due to stability concerns. Medtronic worked with the FDA to address the issue, and the Harmony TPV is once again available throughout the United States. 

The newly developed reference values could have “direct implications for clinical practice” and can be used by any provider to determine whether an adolescent falls within the normal range of measurements for their age group.

In a sudden "shock," Akorn Pharmaceuticals is closing all U.S. sites and laying off its entire workforce after failing to find a potential buyer.